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AbstrACt 
Introduction Bariatric surgery is increasingly recognised 
as an effective treatment option for subjects with type 
2 diabetes and obesity; however, there is no conclusive 
evidence on the superiority of Roux-en-Y gastric bypass 
or sleeve gastrectomy. The Oseberg study was designed 
to compare the effects of gastric bypass and sleeve 
gastrectomy on remission of type 2 diabetes and β-cell 
function.
Methods and analysis Single-centre, randomised, triple-
blinded, two-armed superiority trial carried out at the 
Morbid Obesity Centre at Vestfold Hospital Trust in Norway. 
Eligible patients with type 2 diabetes and obesity were 
randomly allocated in a 1:1 ratio to either gastric bypass 
or sleeve gastrectomy. The primary outcome measures are 
(1) the proportion of participants with complete remission 
of type 2 diabetes (HbA1c≤6.0% in the absence of blood 
glucose-lowering pharmacologic therapy) and (2) β-cell 
function expressed by the disposition index (calculated 
using the frequently sampled intravenous glucose tolerance 
test with minimal model analysis) 1 year after surgery.
Ethics and dissemination The protocol of the current 
study was reviewed and approved by the regional ethics 
committee on 12 September 2012 (ref: 2012/1427/REK 
sør-øst B). The results will be disseminated to academic 
and health professional audiences and the public via 
publications in international peer-reviewed journals and 
conferences. Participants will receive a summary of the 
main findings.
trial registration number NCT01778738;Pre-results.
IntroduCtIon
Bariatric surgery is associated with long-
term weight reduction and improvement of 
comorbidities, but also with adverse events 
and side effects.1 2 Roux-en-Y gastric bypass 
strengths and limitations of this study
 ► Study design—randomised, triple-blinded superior-
ity trial.
 ► Numerous clinically relevant secondary endpoints 
including gastro-oesophageal reflux disease, fatty 
liver disease, cardiovascular risk factors, bone me-
tabolism and patient-reported outcome measures 
covering health-related quality of life, psycholog-
ical distress, eating behaviour and gastrointestinal 
symptoms.
 ► Predefined algorithms for optimising medications 
and supplementations related to primary and sec-
ondary outcomes.
 ► Insulin secretion and action are calculated using 
both oral and intravenous glucose tolerance tests.
 ► The sample size is limited and may, thus, not provide 
sufficient statistical power to detect clinically rele-
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was for many years considered the ‘gold standard’ of 
bariatric surgery, but recently sleeve gastrectomy, a tech-
nically easier and faster to perform procedure, has gained 
popularity and is now the most common bariatric proce-
dure in the USA.3 
For subjects with type 2 diabetes and obesity, bariatric 
surgery is a particularly effective treatment option, and 
a number of randomised trials have demonstrated the 
superiority of surgery over medical care for glycaemic 
control and remission of diabetes.4–9 The improved 
glycaemic homoeostasis following bariatric surgery is 
to a large extent explained by the hypocaloric state 
and weight reduction. However, as improvements often 
are observed even before changes in body weight occur, 
some of the effects appear to be independent of weight 
loss and possibly related to the specific surgical proce-
dure. Both gastric bypass and sleeve gastrectomy reduce 
the size of the stomach, but only gastric bypass includes 
a bypass of the duodenum and proximal small intestine. 
Thus, particularly, after gastric bypass, there is a rapid 
delivery of undigested food to the small intestine that 
enhances the release of gut-derived incretin hormones, 
such as glucagon-like peptide-1 (GLP-1), which further 
stimulate insulin secretion from pancreatic β-cells. 
Indeed, greater enhancement in postprandial GLP-1 
levels have been observed after gastric bypass compared 
with sleeve gastrectomy,10 while others have reported 
no significant differences.11–13 The higher postprandial 
incretin hormone levels may be causally linked with the 
improved β-cell function observed after gastric bypass14–16 
and sleeve gastrectomy.17 However, bariatric surgery is 
also accompanied by changes in other gut-derived and 
pancreatic-derived hormones, which directly or indirectly 
influence glycaemic control.18
A limited number of high-quality studies have compared 
the effect of gastric bypass and sleeve gastrectomy on 
remission of type 2 diabetes. Prior to the initiation of 
the present study, only one randomised controlled study 
had addressed glycaemic control in subjects with type 2 
diabetes and obesity after gastric bypass and sleeve gastrec-
tomy.19 The STAMPEDE trial showed similar reduction in 
HbA1c 1 year after the two surgical procedures. In the 
following years, results from comparable randomised 
controlled trials have been published20–23 including 3 and 
5 years follow-up data from the STAMPEDE trial.4 24 The 
remission rates of type 2 diabetes between the two proce-
dures have not been statistically different in these trials. 
Thus, there is currently no conclusive evidence showing 
the superiority of gastric bypass or sleeve gastrectomy for 
patients with type 2 diabetes and obesity. Also, the impact 
of altered insulin secretion and action, gut microbiota, 
hepatic steatosis and gastric emptying on glycaemia after 
gastric bypass compared with sleeve gastrectomy is not 
clear. Additional relevant outcomes, including changes 
in body weight, obesity-related cardiovascular risk factors, 
symptoms and findings of gastro-oesophageal reflux 
disease, health-related quality of life, psychosocial status, 
eating behaviour, bone health, vitamin and mineral 




The primary objectives of this study are to assess the effects 
of gastric bypass and sleeve gastrectomy on glycaemic 
control, diabetes remission and β-cell function.
Secondary objectives
Secondary objectives are to explore changes in variables 
that are related to the primary endpoints of the study 
(ie, body weight and composition, insulin sensitivity, liver 
fat content, energy intake, stomach emptying rate and 
intestinal microbiota). Moreover, we will explore cardio-
vascular risk factors influenced by weight reduction and 
possibly by changes in gut hormones (ie, blood pressure, 
arterial stiffness, albuminuria and lipids). Finally, we will 
examine possible differences in vitamin and mineral 
deficiencies, bone density, gastro-oesophageal reflux 
disease, hypoglycaemia, dumping syndrome, health-re-
lated quality of life, psychological distress, obesity-related 
symptoms, eating behaviour, nutrient intake, gastrointes-
tinal symptoms and surgical and medical complications 
related to the two operations.
trial design
This study is a single-centre, triple-blinded, two-armed 
superiority trial randomising patients with type 2 diabetes 




The study is carried out at the Morbid Obesity Centre 
at Vestfold Hospital Trust in Norway, a tertiary health-
care centre. The centre performs between 250 and 300 
bariatric procedures (gastric bypass and sleeve gastrec-
tomy) annually and about 25% of the patients have type 2 
diabetes.2 In 2012, when the Oseberg study was initiated, 
sleeve gastrectomy accounted for approximately 10% of 
bariatric procedures at our centre, increasing to approxi-
mately 40% in 2017.
Patient and public involvement
The steering committee includes a patient representative 
(MHK) to make sure that the patients’ voices are heard. 
The burden of the interventions will be assessed using 
several patient-reported outcome measures question-
naires, regarding several aspects of health-related quality 
of life as well as gastrointestinal symptoms. The patients 
will receive summaries of published findings throughout 
the study period.
Inclusion and exclusion criteria
Inclusion criteria
 ► Previously verified body mass index (BMI)≥35.0 kg/
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 ► HbA1c≥6.5% or use of antidiabetic medications with 
HbA1c≥6.1%.
 ► Age≥18 years.
Exclusion criteria
 ► Not able to give informed consent.
 ► Previously major abdominal surgery including bari-
atric surgery (appendectomy, laparoscopic cholecys-
tectomy or gynaecological procedures not included).
 ► Severe endocrine, heart, lung, liver and kidney 
disease, cancer and other medical conditions associ-
ated with significantly increased risk of perioperative 
and postoperative complications.
 ► Drug or alcohol addiction.
 ► Reduced compliance due to severe mental and psychi-
atric conditions.
 ► Pregnancy.
 ► Serum autoantibodies against glutamic acid decar-
boxylase (GAD) or tyrosine phosphatase (IA2).
 ► Regular use (a total of 3 months cumulative use in the 
last 12 months) or treatment the past 2 months with 
systemic corticosteroids.
 ► Severe gastro-oesophageal reflux disease defined as 
Los Angeles classification grade>B, Barrett’s oesoph-
agus and/or hiatus hernia>5 cm.
 ► Elevated oesophageal pressure 
(DCI>5000 mm Hg×s×cm) and symptoms of dysphagia 
and/or painful swallowing.
Interventions
All procedures were performed laparoscopically by expe-
rienced surgeons, and anaesthetists, familiar with obesity 
surgery, were responsible for the general anaesthesia. 
Anaesthesia was induced using propofol and rocuro-
nium, while anaesthesia maintenance was achieved by 
combining desflurane gas and remifentanil infusion. 
Oral trimethoprim-sulpha was used as preoperative anti-
biotic prophylaxis.
The surgical procedures were standardised and similar 
in both gastric bypass and sleeve gastrectomy. Four trocars 
and one Nathanson’s retractor were placed using iden-
tical skin incisions. Pneumoperitoneum was maintained 
at an intra-abdominal pressure of 15 mm Hg using CO2 
insufflation. Dissection and haemostasis were conducted 
using ultrasonic shears (Harmonic Ace Ethicon Endo-
Surgery), and Sonicison, Medtronic (formerly Covidien) 
Echelon Flex (Ethicon EndoSurgery) or EndoGIA Ultra 
Universal Stapler (Covidien) was used for stapling. After 
reducing the intra-abdominal pressure to 10 mm Hg, all 
trocars were removed under visual guidance. Drains were 
not used.
Roux-en-Y gastric bypass
The left crus was dissected free and any hiatal hernia left 
in place. The minor curvature was opened at the second 
vessel and the lesser sac entered. A 25 mL gastric pouch 
was created by firing one horizontal and two vertical 
45 mm blue (Ethicon) or tan (Medtronic, formerly 
Covidien) staple loads. The ligament of Treitz was identi-
fied and a proximal loop of small intestine anastomosed 
to the pouch 60 cm from the ligament of Treitz with one 
firing of a 45 mm linear stapler (white or tan load) using 
the full length of the stapler, creating an antecolic, ante-
gastric alimentary limb. The opening was closed using a 
single row, running absorbable suture. An entero-entero-
anastomosis was then made 120 cm distal of the gastro-en-
teroanastomosis by firing one 45 mm white load (Ethicon) 
or tan (Medtronic, formerly Covidien). The introductory 
opening was closed with a single row, running absorbable 
suture. Finally, the small intestine was divided with one 
45 mm white load (Ethicon) or tan (Medtronic, formerly 
Covidien) between the gastro-entero-enteroanasto-
mosis and the entero-enteroanastomosis in order to 
complete a bypass with an alimentary limb of 120 cm and 
a bileopancreatic limb of 60 cm25. The mesentery was not 
divided, and the omentum was only divided if indicated. 
A leak test with methylene blue was performed and the 
pouch inspected on both sides. The mesenteric defects 
under the entero-enteroanastomosis and at Peterson’s 
space were closed with a running, non-absorbable suture 
or non-absorbable clips.
Sleeve gastrectomy
The greater curvature was dissected free starting 4–5 cm 
from the pylorus up to the angle of Hiss. The left crus was 
visualised and inspected for hiatal hernia. Small sliding 
hernias and wide hiatus were left in situ. The ventricle was 
then lifted and any adhesions in the lesser sac divided. A 
35 Fr bougie was placed down to the pylorus guiding the 
creation of a tubular sleeve with linear staplers. The first 
two loads were always green (Ethicon) or purple (Covi-
dien), while blue (Ethicon) or tan (Medtronic, formerly 
Covidien) loads were used for the rest of the ventricle. 
The last stapler was placed 5 mm laterally to the angle 
of Hiss. The staple line was then inspected and secured 
with clips for additional haemostasis, no oversewing or 
buttressing material was routinely used. A leak test was 
performed with 100 mL methylene blue. The specimen 
was retrieved from one of the trocar sites and visually 
examined for pathology, no routine histological assess-
ment was performed.
Concomitant care
The two intervention groups receive identical concom-
itant care. Both groups completed a low-calorie diet 
(<1200 kcal/day) in the 2 weeks preceding surgery, and, at 
all visits throughout the study, the patients are informed 
about the importance of lifestyle behaviour change, 
diet and physical activity. All patients receive advanced 
medical therapy defined as the implementation of current 
(2012) international guidelines to optimise management 
of hyperglycaemia, elevated blood pressure and dyslipi-
daemia.26–28 Specific algorithms for antidiabetic treat-
ment, blood pressure management, statin therapy, as well 
as management of reflux disease and vitamin and mineral 



















pen: first published as 10.1136/bm




4 Borgeraas H, et al. BMJ Open 2019;9:e024573. doi:10.1136/bmjopen-2018-024573
Open access 




 ► Proportion of participants with complete remission 
of type 2 diabetes (HbA1c≤6.0% in the absence of 
glucose-lowering drug therapy),29 1 year after surgery.
 ► The disposition index measured as a continuous vari-
able,30–32 1 year after surgery.
Secondary outcome measures
Secondary outcome measures are listed in box 1. The 
summary measures for the two surgical groups include 
mean/median and proportions as appropriate. Outcome 
variables include changes from baseline, final values and 
time to events, and will be measured at baseline, 5 weeks, 
16 weeks, 34 weeks, 1 year and annually for 4 more years 
(see table 1).
Participant timeline
A total of 319 out of 1471 patients on the waiting list for 
bariatric surgery had type two diabetes. Among these, 248 
patients fulfilled the inclusion criteria and were invited to 
participate in the study. Ninety patients declined partic-
ipation and the remaining 158 patients gave informed 
consent and underwent the screening examination. A 
total of 30 patients did not meet the inclusion criteria at 
screening and three withdrew their consent. One hundred 
and twenty-five patients underwent baseline examination 
out of whom 16 were excluded due to abnormal gastro-
intestinal findings or other exclusion criteria, leaving 109 
patients to be randomised and subsequently allocated 
to sleeve gastrectomy or gastric bypass. The first patient 
was included in January 2013 and the last patient was 
included in February 2018. Study flow chart and timeline 
are illustrated in figures 1 and 2, respectively.
The Oseberg study includes several test and exam-
inations very shortly after surgery when weight loss is 
expected to be low (5 weeks), after expected maximal 
weight loss (1 year) and during possible weight regain 
(one to 5 years). This comprehensive follow-up enables 
us to evaluate very early, medium and long-term effects of 
gastric bypass and sleeve gastrectomy with varying degrees 
of weight loss. Clinical examinations and tests with sched-
uled time points for assessment are listed in table 1, and a 
list of the blood, urine and faeces samples that have been 
and will be collected, including time points for collec-
tion, is presented in table 2. One-year follow-up will be 
completed in March 2019 and the end of the study period 
is in December 2023.
sample size
This study has two primary endpoints and was powered 
thereafter. On the basis of previous research addressing 
glycaemic response of gastric bypass and sleeve gastrec-
tomy in type 2 diabetic subjects9 19 33 34 remission rates of 
75% and 50%, respectively, were assumed.
Data on disposition index after sleeve gastrectomy 
derived from a frequently sampled intravenous glucose 
tolerance test (FSIGT) was not available before study 
start, and data from a study addressing β-cell function 
after gastric bypass and a low-calorie diet was, therefore, 
used for sample size determination.35 Mean (SD) disposi-
tion index was 268 (232) after gastric bypass and 94 (92) 
after a low-calorie diet. On the basis of these figures mean 
(SD) disposition index after gastric bypass and sleeve 
gastrectomy was estimated to be 270 (160) and 180 (160) 
1 year after surgery, respectively.
box 1 secondary outcome measures
Glucose homoeostasis
 ► HbA1c
 ► Insulin secretion and action
 ► Fasting and stimulated levels of glucose and insulin
 ► Use of antidiabetic medication
 ► Gastrointestinal hormone levels
 ► Gastric emptying rate
body weight and composition
 ► Body weight, body mass index, waist circumference and hip 
circumference
 ► Body composition
obesity-related cardiovascular comorbidities
 ► Resting systolic and diastolic blood pressure
 ► Twenty-four hours ambulatory blood pressure
 ► Use of blood pressure lowering drugs
 ► Pulse wave velocity
 ► Cholesterol and triglyceride levels
 ► Use of lipid-lowering agents
 ► Obstructive sleep apnoea score
 ► Microalbuminuria
Gastrointestinal tract and liver
 ► Gastro-oesophageal reflux disease and oesophageal motility
 ► Fatty liver disease
 ► Gut microbiota and microbiome
 ► Self-reported gastrointestinal symptoms
Physical activity
 ► Measured physical activity
 ► Self-reported physical activity
Energy intake and eating behaviour
 ► Food frequency
 ► Food tolerance
 ► Eating patterns
obesity specific well-being
 ► Health-related quality of life
 ► Obesity-related symptoms
 ► Psychological distress
harms
 ► Surgical and medical complications
 ► Hypoglycaemic episodes and early dumping
 ► Vitamin and mineral deficiencies
 ► Bone mineral density and metabolism
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Given a 5% significance level and 80% power and an 
equal distribution to the two groups, a total study sample 
of 110 (remission) or 100 (disposition index) subjects was 
required to reveal a difference between groups. In order 
to accommodate possible dropouts (5% in previous study 
at our centre),9 we planned to include 120 subjects in the 
study. Due to a higher than expected number of excluded 
patients after baseline examinations, the baseline study 
population was increased to 125.
recruitment
The electronic medical records of all patients on the 
waiting list for bariatric surgery at the Morbid Obesity 
Centre were reviewed by one of the principal investiga-
tors (DH). Patients eligible for inclusion were contacted 
by phone (DH) and invited to an information meeting a 
few months prior to surgery. Patients who then approved 
participation signed the informed consent and under-
went a screening procedure.
Allocation—sequence generation and concealment
The allocation sequence was created by one of the 
bariatric surgeons (MS), not involved in the recruitment 
or follow-up of the patients, using a computerised random 
number generator ( randomization. com) with a 1:1 allo-
cation using blocks sizes of 10. Opaque envelopes were 






















Visit 1 2 3 4 5 6 7 8–10 11
Demographic data x
Comorbidities x
Regular medication x x x x x x x
Clinical examination x x x x x x x x
Physician consultation x x x x x x x x
Inclusion and exclusion 
criteria
x
Signed informed consent x
Blood samples* x x x x x x x x x
Urine samples* x x x x
Faecal sample* x x x x
Pulse wave velocity x x x x
Bioelectrical impedance 
analysis
x x x x x x x
ECG x x x
OGTT and FSIGT x x x x
PROMs questionnaires 
(web)




DEXA x x x
MRI x x x x
Upper endoscopy x x x
Manometry x x x




x x x x
SenseWear x x x x
ApneaLink x x x x
Hypoglycaemia/dumping x x x x x x x
Adverse events x x x x x x x
*See table 2.
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sequentially numbered, and a note with the procedure 
to be conducted, according to the randomisation list, 
was placed inside the envelope. The envelopes were then 
sealed and stored inside locked cabinets. Only authorised 
staff members, including the person who uploaded the 
sequence to the web-based randomisation service, have 
access to the allocation sequence. The investigators 
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in contact with the patients, do not have access to the allo-
cation sequence. The allocation for each specific patient 
was revealed, to the surgical staff only, in the operating 
room on the day of surgery. Afterwards, the envelope with 
the randomisation code was resealed and stored in the 
coordinating office in locked cabinets. The surgical staff 
were not involved with patient follow-up after the surgical 
procedure.
blinding
The triple blinding refers to blinding of patients, study 
personnel engaged in all visits until the 1-year follow-up 
and the person(s) analysing the primary outcomes. 
Surgical incisions from the two procedures are identical, 
and postsurgical follow-up and treatment are similar for all 
patients. The randomisation code will remain concealed 
until data for the primary outcomes have been collected 
at 1 year. The research physician is then be responsible 
for including the actual type of surgery in the patient’s 
electronic medical record and for informing the patient. 
The code will only be broken during the first year if there 
is an unexpected complication or a need for reoperation. 
A list linking name and study identification number with 
study procedure is available at the study office and in the 
emergency department—all patients are aware of this. 
The research physician must report all code breaks (with 
reason) in the case report form.
data collection methods
Primary outcomes
Remission of type 2 diabetes
Whole blood HbA1c will be analysed on a Tosoh 
high-performance liquid chromatography G8 analyser 
(Tosoh Corporation, Tokyo, Japan) with reagents from 
the supplier. The analytical variation (CVat) is estimated 
to be 1.4%.
Disposition index
The disposition index, a valid surrogate measure of β-cell 
function, is the product of insulin sensitivity and the 
insulin secretory response to a glucose challenge (insulin 
sensitivity index (Si)×acute insulin response (AIRg)). Si 
and AIRg will be estimated with the Bergman minimal 
model (MINMOD Millennium software),36 which uses 
glucose and insulin data obtained from a FSIGT.30–32 
The laboratory analyses used for quantifying insulin and 
glucose are shown in table 2.
Execution of the FSIGT: The patients are asked to avoid 
vigorous physical activity 1 week prior to the test. The 
patients must also terminate treatment with long-acting 
GLP-1 analogues and other antidiabetic medications 6 
weeks and 48 hours prior to the test, respectively. The 
participants are not allowed to drink (up to 2 dL of water 
is allowed), eat or smoke 8 hours prior to the test. Other 
morning medications are delayed until after the tests. 
A cannula is inserted into a cubital vein and the cannu-
lated arm wrapped in a heat pad throughout the exper-
iment for the collection of arterialised blood samples. A 
cannula is then inserted in the contralateral cubital vein 
for glucose and insulin infusion. Due to patient safety, the 
upper limit of fasting blood glucose prior to FSIGT was 
set to <20 mmol/L. Blood samples are drawn two times 
before (−5 and 0 min) and after 2, 4, 8, 19, 22, 30, 40, 
50, 70, 90 and 180 min after the intravenous glucose load 
(300 mg/kg body weight). After 20 min, a bolus of insulin 
is administrated (0.03 U/kg body weight). Blood will, at 
all time points, be collected in (1) one tube, which will 
be centrifuged after 30 min, serum will then be put on 
ice and stored at −80°C until the analysis of insulin and 
(2) one tube containing lithium heparin, which will be 
centrifuged immediately before the analysis of plasma 
glucose the same day. See table 2 for method principles, 
sample matrix, units and analytical precision of glucose 
and insulin analysis.
Secondary outcomes
See online supplementary file 2 for data collection 
methods of the secondary outcomes. Routine laboratory 
measurements will be performed at the Central Labora-
tory, Vestfold Hospital Trust. The laboratory is accredited 
according to NS-EN ISO 15189 and serves as the main 
analytical facility in the hospital. Complete blood count 
will be analysed on Sysmex XN-9000 with reagents from 
the supplier (Sysmex Corporation, Kobe, Japan). General 
clinical chemistry and immunochemistry were analysed 
on Cobas 8000 with modules ISE, c702 and e801 (Roche 
Diagnostics, Basel, Switzerland). Thiamin, bone markers, 
insulin, C peptide, Anti-GAD and Anti-IA2 will be analysed 
at Oslo University Hospital using established methods. A 
complete list of method principles, sample matrix, units 
and analytical precision are given in table 2.
Retention
Once a participant is included, every reasonable effort is 
made to prevent attrition through the entire study period. 
In addition to the planned visits, all participants have, 
during the last 2 years, received two letters in connection 
with milestones and holidays. Distribution of letters will 
continue throughout the entire study period. Loss to 
follow-up is estimated to be 5% or less.9
data management
Authorised individuals enter all data electronically and 
into the original study forms. Data integrity is enforced 
through referential data rules, valid values and range 
checks. Data are stored on a secure and password-pro-
tected electronic research server. The original study 
forms are stored in locked cabinets at the study location. 
Participant files will be kept in storage for a period of at 
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Table 2 Method principles, sample matrix, units and analytical precision of laboratory measurements
Analyte Method principle Sample matrix Unit
Precision
(CV, analytical)
Time point for 
collection
(visit number)*
Ferritin ECLIA Serum µg/L 7% 1–11
Iron Photometry Serum µmol/L 4% 1–11
Transferrin Photometry Serum 1–11
Vitamin B12 ECLIA Serum pmol/L 12% 1–11
Folic acid ECLIA Serum nmol/L 12% 1–11
C reactive protein Photometry Serum mg/L 5% 1–11
Creatinine Photometry Serum µmol/L 2.5% 1–11
Sodium ISE Serum mmol/L 1.0% 1–11
Potassium ISE Serum mmol/L 1.2% 1–11
Calcium Photometry Serum mmol/L 1.5% 1–11
Magnesium Photometry Serum mmol/L 3.0% 1–11




2, 4, 7 and 11
Total protein Photometry Serum g/L 2.5% 1–11
Uric acid Photometry Serum µmol/L 4.0% 1–11
Glucose Photometry Serum/plasma mmol/L 2.0% 1–4, 7 and 11
Alanine 
aminotransferase
Photometry Serum U/L 5% 1–11
Aspartate 
transaminase
Photometry Serum U/L 9.0% 1–11
Alkaline 
phosphatase
Photometry Serum U/L 3.0% 1–11
Gamma-glutamyl 
transpeptidase
Photometry Serum U/L 3.0% 1–11
Lactate 
dehydrogenase
Photometry Serum U/L 5.5% 1–11
Creatine kinase Photometry Serum
Urine
U/L 5.0% 1–11
2, 4, 7 and 11
Bilirubin Photometry Serum µmol/L 5.0% 1–11
Amylase Photometry Serum 1–11
Total cholesterol Photometry Serum mmol/L 2.5% 1–11
HDL cholesterol Photometry Serum mmol/L 3.0% 1–11
LDL cholesterol Photometry Serum mmol/L 3.0% 1–11
Triglycerides Photometry Serum mmol/L 3.0% 1–4, 7 and 11
Thyroid-stimulating 
hormone
ECLIA Serum mIE/L 5.0% 1–11
Unbound 
triiodothyronine
ECLIA Serum pmol/L 5.0% 1–11
Unbound thyroxine ECLIA Serum pmol/L 5% 1–11
Parathyroid 
hormone
ECLIA Plasma pmol/L 6.0% 1–11
25-OH-vitamin D ECLIA Serum nmol/L 6.5% 1–11
Β-human chorionic 
gonadotropin†
ECLIA Serum IE/L 5.0% 1
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statistical methods
Data will be analysed according to both the interven-
tion into which patients were randomised (intention-
to-treat analysis) and per-protocol. Descriptive data will 
be presented as mean (SD), median (range) or number 
(%). Between-group comparisons will be analysed using 
independent samples t-test, repeated measures analysis of 
variance, mixed model analysis and Mann-Whitney U test 
for continuous variables and χ2, Fisher’s exact test and 
binary logistic regressions for repeated measures for cate-
gorical variables as appropriate. Regression analysis will 
be used for the exploration of the independent effects 
of weight reduction and other variables on primary and 
secondary outcomes.
data monitoring
The steering committee consists of a team of healthcare 
professionals, researchers and a patient representative. 
Members of the steering committee meet every sixth 
month and safeguard the interests of trial participants 
and monitor the overall conduct of the clinical trial. 
Adverse events are consecutively reported. Harms are 




The study protocol was registered in an international 
trial register ( ClinicalTrials. gov) on 03 December 2012. 
See online supplementary file 3 for a brief structured 
summary of the study (WHO Trial Registration Data Set). 
The study is conducted according to the Declaration of 
Helsinki.
Protocol amendments
Significant amendments to the protocol have been/will 
only be made after ethical approval by the regional ethics 
committee. For previous amendments, see online supple-
mentary file 4.
Informed consent
After a thorough evaluation of the existing literature prior 
to the approval of the study protocol in 2012, and after 
balancing clinical effects and side-effects, no evidence 
was found suggesting gastric bypass or sleeve gastrectomy 
to be a better choice for patients with type 2 diabetes. 
Research assistants and patients were informed about the 
lack of evidence before the start of the study, and one 
of the principal investigators (DH) obtained informed 
consents in face-to-face meetings.
Analyte Method principle Sample matrix Unit
Precision
(CV, analytical)
Time point for 
collection
(visit number)*










Thiamin HPLC Serum nmol/L 4.5% 2 and 4–11
Bone alkaline 
phosphatase









type I N-terminal 
propeptide
ECLIA Serum µg/L 5% 2 and 4–11
Insulin ECLIA Serum pmol/L 4% 2, 4, 7 and 11
C peptide ECLIA Serum pmol/L 4% 2, 4, 7 and 11
Anti-GAD IP Serum ai 0.25 ai 25%
1.45 ai 8%
1
Anti-IA2 IP Serum ai 0.32 ai 18%
1.66 ai 12%
1




*Fasting blood samples visit 2, 4, 7 and 11.
†Women only.
ai, antibody index; CLIA, chemiluminescent immunoassay; CV, coefficient of variation; ECLIA, electro-CLIA; HPLC, high-performance liquid 
chromatography; IP, immunoprecipitation; ISE, ion selective electrode.
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Ancillary studies
Additional biological samples (urine, blood, serum, 
plasma and faeces) will be obtained and stored for use in 
future studies. Information about storage and analyses of 
biological samples was covered in the original informed 
consent for the Oseberg study.
Confidentiality
All participants are given a study ID, which will be used 
during data analyses. The key linking name and study 
ID is kept on a password-protected server. Participants’ 
study information will not be released outside of the study 
without the written permission of the participant.
Access to data
Selected study personnel, authorised to enter data elec-
tronically, and investigators within the Oseberg study 
have access to the final trial data set. Researchers within 
the Oseberg study must seek approval from the principal 
investigators prior to initiating data analyses.
Ancillary and post-trial care
The patients will receive post-trial follow-up according to 
national guidelines.37
dissemination
The protocol and the results of the study (primary and 
secondary endpoints at 1 and 5 years) will be published in 
international peer-reviewed journals in accordance with 
the ICMJE criteria for authorship (http://www. icmje. 
org/ ethical_ 1author. html). The executive and steering 
committees will actively contribute to the involvement 
and inclusion of authors and the order of authorships 
in the planning of publications. The results will also be 
disseminated through networks of scientists, conferences, 
professionals, and policymakers and commissioners of 
weight management.
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